Plus Therapeutics (PSTV) 10-K 9 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Jan. 31, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	1,095,981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 36.4
Entity Common Stock, Shares Outstanding		59,819,615
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 9,550	$ 12,560
Accounts receivable, net of reserves of $167 in 2017 and 2016	145	1,242
Restricted cash	675	350
Inventories, net	3,183	3,725
Other current assets	1,311	870
Total current assets	14,864	18,747
Property and equipment, net	3,052	1,157
Other assets	2,570	2,336
Intangibles, net	7,207	8,447
Goodwill	3,922	3,922
Total assets	31,615	34,609
Current liabilities:
Accounts payable and accrued expenses	4,790	5,872
Current portion of long-term obligations, net of discount	13,624	6,629
Total current liabilities	18,414	12,501
Deferred revenues	94	97
Long-term deferred rent and other	107	17
Long-term obligations, net of discount, less current portion	0	11,008
Total liabilities	18,615	23,623
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 23,500 shares issued; 2,431 shares outstanding in 2017 and no shares outstanding in 2016	0	0
Common stock, $0.001 par value; 75,000,000 shares authorized; 57,825,729 and 21,707,890 shares issued and outstanding in 2017 and 2016, respectively	58	22
Additional paid-in capital	413,304	388,769
Accumulated other comprehensive income	1,387	1,258
Accumulated deficit	(401,749)	(379,063)
Total stockholders’ equity	13,000	10,986
Total liabilities and stockholders’ equity	$ 31,615	$ 34,609

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Accounts receivable, reserves	$ 167	$ 167
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	23,500	23,500
Preferred stock, shares outstanding (in shares)	2,431	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	57,825,729	21,707,890
Common stock, shares outstanding (in shares)	57,825,729	21,707,890

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Product revenues	$ 2,689	$ 4,656
Cost of product revenues	1,318	2,170
Amortization of intangible assets	1,225	545
Gross profit	146	1,941
Development revenues:
Government contracts and other	3,722	6,724
Total development revenues	3,722	6,724
Operating expenses:
Research and development	11,678	16,197
Sales and marketing	3,593	3,611
General and administrative	7,594	8,563
Total operating expenses	24,551	28,371
Operating loss	(20,683)	(19,706)
Other income (expense):
Interest income	33	19
Interest expense	(2,049)	(2,592)
Other income, net	13	233
Total other expense	(2,003)	(2,340)
Net loss	(22,686)	(22,046)
Beneficial conversion feature for convertible preferred stock	(3,977)	0
Net loss allocable to common stockholders	$ (26,663)	$ (22,046)
Basic and diluted net loss per share allocable to common stockholders	$ (0.82)	$ (1.28)
Basic and diluted weighted average shares used in calculating net loss per share allocable to common stockholders	32,389,831	17,290,933
Comprehensive loss:
Net loss	$ (22,686)	$ (22,046)
Other comprehensive income – foreign currency translation adjustments	129	262
Comprehensive loss	(22,557)	(21,784)
Azaya Therapeutics, Inc. [Member]
Operating expenses:
In process research and development acquired from Azaya	$ 1,686	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Series B Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Series B Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 12,206				$ 13		$ 368,214		$ 996	$ (357,017)
Balance (in shares) at Dec. 31, 2015					13,003,893
Share-based compensation	1,080						1,080
Issuance of common stock under employee stock purchase plan	6						6
Issuance of common stock under employee stock purchase plan (in shares)					30,744
Sale/Issuance of common stock	19,478				$ 9		19,469
Sale/Issuance of common stock (in shares)					8,673,253
Foreign currency translation adjustment and accumulated other comprehensive income	262								262
Net loss	(22,046)									(22,046)
Balance at Dec. 31, 2016	$ 10,986				$ 22		388,769		1,258	(379,063)
Balance (in shares) at Dec. 31, 2016	21,707,890				21,707,890
Share-based compensation	$ 753						753
Issuance of common stock under employee stock purchase plan	1						1
Issuance of common stock under employee stock purchase plan (in shares)					1,200
Sale/Issuance of common stock	12,716	$ 8,767			$ 12		12,704	$ 8,767
Sale/Issuance of common stock (in shares)				10,000	12,237,079
Conversion of Series B Convertible Preferred Stock into common stock		23				$ 23
Conversion of Series B Convertible Preferred Stock into common stock (share)				(7,569)		22,706,319
Issuance of common stock as part of Azaya Therapeutics acquisition, net	2,311				$ 1		2,310
Issuance of common stock as part of Azaya Therapeutics acquisition, net (shares)					1,173,241
Beneficial conversion feature related to Series B Convertible Preferred Stock		3,977						3,977
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock		$ (3,977)						$ (3,977)
Foreign currency translation adjustment and accumulated other comprehensive income	129								129
Net loss	(22,686)									(22,686)
Balance at Dec. 31, 2017	$ 13,000				$ 58		$ 413,304		$ 1,387	$ (401,749)
Balance (in shares) at Dec. 31, 2017	57,825,729		2,431		57,825,729

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (22,686)	$ (22,046)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,151	1,182
Amortization of deferred financing costs and debt discount	707	954
Joint venture acquisition obligation accretion	0	24
Provision for expired inventory	340	172
Share-based compensation expense	753	1,080
Gain on asset disposal	(42)	(127)
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	1,129	(179)
Inventories	251	471
Other current assets	(593)	633
Other assets	(94)	(764)
Accounts payable and accrued expenses	(1,817)	(673)
Deferred revenues	(3)	(8)
Long-term deferred rent	90	(252)
Net cash used in operating activities	(18,128)	(19,533)
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(295)	(67)
Proceeds from sale of assets	113	131
Change in restricted cash	(325)	0
Net cash (used in) provided by investing activities	(1,708)	64
Cash flows from financing activities:
Principal payments on long-term obligations	(4,720)	0
Joint venture purchase payments	0	(1,774)
Proceeds from sale of common stock	23,613	21,467
Costs from sale of common stock	(2,078)	(2,084)
Net cash provided by financing activities	16,815	17,609
Effect of exchange rate changes on cash and cash equivalents	11	82
Net decrease in cash and cash equivalents	(3,010)	(1,778)
Cash and cash equivalents at beginning of period	12,560	14,338
Cash and cash equivalents at end of period	9,550	12,560
Cash paid during period for:
Interest	1,364	1,618
Supplemental schedule of non-cash investing and financing activities:
Issuance costs paid in common stock	0	189
Conversion of preferred stock into common stock	23	0
Fair value of Series B Convertible Preferred Stock beneficial conversion feature	3,977	0
Azaya Therapeutics, Inc. [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
In process research and development acquired from Azaya Therapeutics	1,686	0
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(1,201)	0
Supplemental schedule of non-cash investing and financing activities:
Common stock issued in payment for the assets acquired	$ 2,311	$ 0

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Operations	1. Organization and Operations The Company Cytori Therapeutics, Inc. (Nasdaq: CYTX) is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Principles of Consolidation The accompanying consolidated financial statements include our accounts and those of our subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company has five wholly-owned subsidiaries located in Japan, United Kingdom, Switzerland, India and Spain that have been established primarily to support our sales and marketing activities in these regions. Reverse Stock Split On May 10, 2016, following stockholder and Board approval, an amendment (the “Amendment”) to the Company’s amended and restated certificate of incorporation, as amended, was filed and declared effective, which Amendment effectuated a one-for-fifteen (1:15) reverse stock split of the Company’s (i) outstanding common stock, and (ii) common stock reserved for issuance upon exercise of outstanding warrants and options (the “1:15 Reverse Stock Split”). Upon effectiveness of the 1:15 Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 200 million shares (as of May 10, 2016) to approximately 13.3 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 16 million shares to approximately 1.1 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 6.5 million common shares to approximately 0.4 million common shares. In connection with the 1:15 Reverse Stock Split, the Company also decreased the total number of its authorized shares of common stock from 290 million to 75 million. The number of authorized shares of preferred stock remained unchanged. Following the 1:15 Reverse Stock Split. The Company adjusted stockholders’ equity to reflect the 1:15 Reverse Stock Split by reclassifying an amount equal to the par value of the shares eliminated by the split from common stock to the additional paid-in capital during the first quarter of fiscal 2016, resulting in no net impact to stockholders' equity on our consolidated balance sheets. The Company’s shares of common stock commenced trading on a split-adjusted basis on May 12, 2016. Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants and equity incentive plans for all periods presented. Certain Risks and Uncertainties Our prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. Our future viability largely depends on our ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that our new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. The development of medical devices for specific therapeutic applications is subject to a number of risks, including research, regulatory and marketing risks. There can be no assurance that our development stage products will overcome these hurdles and become commercially viable and/or gain commercial acceptance. Liquidity and Going Concern We incurred net losses of $22.7 million and $22.0 million for the years ended December 31, 2017 and 2016, respectively. We have an accumulated deficit of $401.7 million as of December 31, 2017. Additionally, we have used net cash of $18.1 million and $19.5 million to fund our operating activities for the years ended December 31, 2017 and 2016, respectively. The Company does not have sufficient capital to fund operations through one year from the issuance date of these consolidated financial statements. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Further, the Loan and Security Agreement, with Oxford Finance, LCC (“Oxford”), as further described in Note 8, requires maintaining a minimum of $1.5 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement. Based on our cash and cash equivalents on hand of approximately $9.6 million at December 31, 2017, the Company estimates that it will need to raise additional capital and/or obtain a waiver or restructure the Loan and Security Agreement in the near term to avoid defaulting under our $1.5 million minimum cash/cash equivalents covenant. To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed underwritten public offering, Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) and the 2016 and 2017 Rights Offerings (each defined below), our at-the-market (“ATM”) equity facility, the Loan and Security Agreement and gross profits. We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. Our inability to raise additional cash will have a material and adverse impact on operations and will cause us to default on our loan. On June 15, 2016, we closed a rights offering originally filed under Form S-1 registration statement in April 2016. Pursuant to the 2016 Rights Offering (as defined below in Note 11), we sold an aggregate of 6,704,852 units consisting of a total of 6,704,852 shares of common stock and 3,352,306 warrants, with each warrant exercisable for one share of common stock at an exercise price of $3.06 per share, resulting in total gross proceeds to Cytori of $17.1 million. See Note 11 for further discussion on the 2016 Rights Offering. On December 22, 2016, we entered into a purchase agreement and a registration rights agreement, with Lincoln Park pursuant to which we have the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million of shares of the Company’s common stock over the 30-month period following March 31, 2017, subject to the satisfaction of certain conditions. See Note 11 for further discussion on the Lincoln Park agreement. On April 11, 2017, we entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC (“Maxim”) relating to the issuance and sale of 8.6 million shares of our common stock, par value $0.001 per share. The price to the public in the offering was $1.10 per share. Maxim agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.0395 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and offering expenses incurred by the Company. The offering closed on April 17, 2017. In addition, under the terms of the Underwriting Agreement, we granted Maxim a 45-day option to purchase up to 944,000 additional shares of common stock. On May 31, 2017, Maxim exercised its option and purchased 849,000 shares at $1.10 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses incurred by us. On September 5, 2017, we received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a period of 180 calendar days, or until March 5, 2018, in which to regain compliance. We were granted an additional compliance period of 180 calendar days, or until September 4, 2018, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. On November 28, 2017, we closed a rights offering originally filed under a Form S-1 registration statement in August 2017 (“2017 Rights Offering”). Pursuant to the 2017 Rights Offering, the Company sold an aggregate of 10,000 units consisting of a total of 10,000 shares of Series B Convertible Preferred Stock, immediately convertible into approximately 30,000,000 shares of common stock and 18,000,000 warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.3333 per share, resulting in total net proceeds to the Company of $8.8 million. These warrants only become exercisable upon stockholder approval. We continue to seek additional capital through product revenues, strategic transactions, including extension opportunities under our awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this could negatively affect our ability to achieve corporate growth goals. Should we be unable to raise additional cash from outside sources, this will have a material adverse impact on our operations. The accompanying consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. Reclassifications Certain immaterial reclassifications have been made to certain of the prior years’ consolidated financial statements to conform to the current year presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring expense related to our in-process research and development acquisition, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary. Cash and cash equivalents We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents includes cash in readily available checking and savings accounts. We held no investments as of December 31, 2017 and 2016. We maintain our cash at insured financial institutions. Restricted Cash Restricted cash consists of cash invested in certificate of deposits used as collateral for the issuance of letters of credit pursuant to lease agreements for leasing of property at 3020 and 3030 Callan Road, San Diego, CA, which requires us to execute a letter of credit for $0.2 million naming the landlord as a beneficiary as of December 31, 2017. In addition, in connection with the new lease (see Note 7) we executed in 2017, we issued a letter of credit in favor of that landlord in the amount of $0.5 million, which will remain in effect for the term of the lease. Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company periodically assesses the collectability of accounts receivable on a specific customer basis considering factors such as evaluation of collectability, historical collection experience, the age of accounts receivable and other currently available evidence of the collectability, and records an allowance for doubtful accounts for the estimated uncollectible amount. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Inventories Inventories include the cost of material, labor, and overhead related to Celution devices, consumable kits, and reagents, and are stated at the lower of cost, determined on the first-in, first-out (FIFO) method, or net realizable value. We periodically evaluate our on-hand stock and make appropriate provisions for any stock deemed excess or obsolete. Manufacturing costs resulting from lower than “normal” production levels are expensed as incurred. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. Impairment We assess certain of our long-lived assets, such as property and equipment and intangible assets other than goodwill, for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. We recognized no impairment losses during any of the periods presented in these financial statements. Goodwill and Intangibles Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, there is an indication that goodwill may be impaired and the amount of the loss, if any, is measured by performing step two. Under step two, the impairment loss, if any, is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. There was no indication of impairment of goodwill for all periods presented. Separable intangible assets that have finite useful lives are amortized over their respective useful lives. As part of the May 2013 acquisition of the Joint Venture (see Note 3), we acquired intangible assets which consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. The technology was valued at $9.4 million and is being amortized on a straight-line basis over a useful life of eleven years, commensurate with the expected cash flows. The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2017 and 2016 are as follows (in thousands): December 31, 2017 December 31, 2016 Intangibles, net: Beginning balance $ 8,447 $ 9,031 Increase — — Amortization (1,240 ) (584 ) Ending balance 7,207 8,447 Goodwill, net: Beginning balance 3,922 3,922 Increase (decrease) — — Ending balance 3,922 3,922 Total goodwill and other intangibles, net $ 11,129 $ 12,369 Revenue Recognition Product Sales We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We evaluate customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction and defer revenues until collectability is reasonably assured. For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books. Concentration of Significant Customers & Geographical Sales For the year ended December 31, 2017, our sales were concentrated with respect to five direct customers, which comprised 68% of our product revenue recognized. One licensee and one direct customer accounted for 77% of total outstanding accounts For the year ended December 31, 2016, our sales were concentrated with respect to two distributors and three direct customers, which comprised 65% of our product revenue recognized. Two direct customers accounted for 57% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2016. Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2017 2016 Product Revenues % of Total Product Revenues % of Total Americas $ 345 13 % $ 936 20 % Japan 1,924 71 % 3,279 71 % EMEA 344 13 % 379 8 % Asia Pacific 76 3 % 62 1 % Total product revenues $ 2,689 100 % $ 4,656 100 % Development Revenues We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $3.7 million and $6.7 million in BARDA revenue for the years ended December 31, 2017 and 2016, respectively. Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for our research and development employees. Also included in research and development expenditures are costs incurred to support the government reimbursement contract, including $3.5 million and $6.3 million of qualified expenses that were incurred for the years ended December 31, 2017 and 2016, related to our government contract with BARDA. Deferred Financing Costs and Other Debt-Related Costs Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2017 and 2016, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. Share-Based Compensation We recognize the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the award. We estimate the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and applied to all employee awards as a single group as we do not expect (nor does historical data suggest) substantially different exercise or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. Segment Information For the years ended December 31, 2017 and 2016, the Company is managed as a single operating segment, therefore we report our results in one operating segment. Loss Per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the years ended December 31, 2017 and 2016, as their inclusion would be antidilutive. Potentially dilutive securities excluded from the calculations of diluted loss per share were 20.5 million as of December 31, 2017, which includes 19.5 million outstanding warrants and 1.0 million options and restricted stock awards. Potentially dilutive securities excluded from the calculations of diluted loss per share were 4.2 million as of December 31, 2016. Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. We will adopt the standards beginning the first quarter of 2018 using the modified retrospective method. We have completed our assessment of the new standard and are evaluating the impact of the new required disclosures. Overall, we do not expect the timing or amounts related to the revenue recognition under the new standards to be materially different from our current revenue recognition policy. Our product revenues are recognized at a point in time, which is when we control transfers to the customer. We will make accounting policy elections to 1) treat shipping and handling activities that occur after the customer obtains control of the goods as fulfillment costs and 2) exclude sales (and similar) taxes from the measurement of the transaction price. Because we have no open contracts as of December 31, 2017, there will be no cumulative effect of applying the new standards. In February 2016, the FASB issued ASU 2016-02, Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of certain cash receipts and cash payments In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation Recently Adopted Accounting Pronouncements In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business

Transactions with Olympus Corpo

Transactions with Olympus Corporation	12 Months Ended
	Dec. 31, 2017
Joint Venture Termination Agreement [Abstract]
Transactions with Olympus Corporation	3 . Transactions with Olympus Corporation Under our Joint Venture Termination Agreement (“Termination Agreement”), dated May 8, 2013, with Olympus Corporation (“Olympus”), we were required to pay Olympus a total purchase price of $6.0 million within two years of the date of the Termination Agreement. Pursuant to amendments to the Termination Agreement, dated April 30, 2015 and January 8, 2016, the Company’s repayment obligations were extended through May 8, 2016. We made payments under the Termination Agreement totaling approximately $4.2 million through December 31, 2015, as well as separate payments of $0.5 million each in January 2016 and April 2016, and paid the remaining balance of $0.8 million before the May 8, 2016 due date. There were no outstanding obligations to Olympus as of December 31, 2017.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value	4 . Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. • Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. As of December 31, 2017 and 2016, we did not have any assets or liabilities measured at fair value presented on our balance sheets. Financial Instruments We disclose fair value information about all financial instruments, whether or not recognized in the balance sheets, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at December 31, 2017 and 2016, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts. The carrying amounts for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value. At December 31, 2017 and 2016, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows (in thousands): December 31, 2017 December 31, 2016 Fair Value Carrying Value Fair Value Carrying Value Debt $ 13,427 $ 13,624 $ 17,611 $ 17,637 Carrying value is net of debt discount of $0.4 million and $1.2 million as of December 31, 2017 and 2016, respectively. The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs, primarily the effective interest rate, to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means. Nonfinancial Assets and Liabilities We apply fair value techniques on a non-recurring basis associated with: (1) valuing potential impairment losses related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles—goodwill and other; and (2) valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment.

Asset Purchase Agreement with A

Asset Purchase Agreement with Azaya Therapeutics	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Asset Purchase Agreement with Azaya Therapeutics	5. Asset Purchase Agreement with Azaya Therapeutics On February 15, 2017 (the “Closing Date”), we completed the acquisition from Azaya Therapeutics, Inc. (“Azaya”) of certain tangible assets which consisted of a research lab, equipment and leasehold improvements and the assumption of certain of liabilities of Azaya, pursuant to an Asset Purchase Agreement (the “Agreement”). The book value of the tangible assets acquired was approximately $3.0 million at the acquisition date. The assets acquired are located in a facility rented in San Antonio, TX, by Cytori. In addition, pursuant to the Agreement, we acquired intangible assets comprised of two drug candidates in process research and development (IPR&D) stage (i) ATI-0918, a generic bioequivalent formulation of Doxil ® ® At the closing of the acquisition, we (i) issued 1,173,241 of shares of our common stock in Azaya’s name, (A) 879,931 of which were delivered to Azaya promptly after the Closing, and (B) 293,310 of which were deposited into a 15-month escrow pursuant to a standard escrow agreement; and (ii) assumed the obligation to pay approximately $1.8 million of Azaya’s existing payables, all of which December In addition, as of the Closing Date, the Company committed to certain contingent consideration to: (i) pay Azaya fixed commercialization milestone payments based upon achievement of certain net sales milestones for ATI-0918; (ii) make certain earn-out payments to Azaya equal to a mid-single-digit percentage of net sales of ATI-0918; and (iii) make certain earn-out payments to Azaya equal to a low single-digit percentage of net sales of any product (ATI-0918 is the “Generic Product” and ATI-1123 is the “Patented Product”), including ATI-1123, that practices a claim in the related patent assigned by Azaya to the Company (the “ATI-1123 Patent”). Our aggregate earn-out payment obligations to Azaya from global net sales of both ATI-0918 and any Patented Product will not exceed $100.0 million (the “Earn-Out Cap”). Further, the Agreement provides that if we enter into certain assignments, licenses or other transfers of rights to a Patented Product or the ATI-1123 Patent, we will pay Azaya a percentage in the low to mid-teens of the consideration received by us, provided, that our aggregate payment obligation to Azaya for any such assignment, license or other transfer of rights will not exceed $50.0 million. If the Company or its successors, sublicenses or transferees sells a competing product to ATI-0918 at any time prior to satisfaction of the Earn-Out Cap, other than because ATI-0918 fails to receive marketing authorization from the European Medicines Agency within a certain period of time or fails to generate a minimum threshold of net sales within a pre-determined amount of time, then 50% of the net sales of such competing product would be deemed to be net sales of ATI-0918 under the Agreement for purposes of calculating commercialization milestone payments and earn-out payments. We accounted for the acquisition as an asset acquisition because the acquired set of assets did not meet the definition of a business. The total consideration of $4.3 million, which consists of $2.3 million related to the fair value of the common stock issued to Azaya at the acquisition date, $1.8 million in assumed liabilities and $0.2 million in acquisition costs, was allocated to the assets acquired based on their relative fair values at the time of acquisition. All other future payments were deemed contingent consideration which will be accounted for when the contingency is resolved and the consideration is paid or becomes payable. When determining the fair value of tangible assets acquired, the Company estimated the cost to replace the tangible asset with a new asset, taking into consideration such factors as age, condition and the economic useful life of the asset. When determining the fair value of intangible assets acquired, the Company used a discounted cash flow model with key inputs being the applicable discount rate, market growth rates and the timing and amount of future cash flows. The acquired IPR&D is in the early stage of development. Additional research, pre-clinical studies, and regulatory approvals must be successfully completed prior to selling any product. Because there is no current alternative use for the IPR&D, following the authoritative accounting guidance, the Company has expensed it in full on the Closing Date. The Company measured the fair value of the shares issued as consideration in the acquisition of the assets based on the stock price at the acquisition date. Transaction costs directly related to the acquisition of the assets have been capitalized. The total consideration was allocated on a relative fair value basis to the assets acquired, as follows (in thousands): February 15, 2017 Tangible assets $ 2,586 Intangible assets 1,686 Total assets $ 4,272 Accounts payable $ 1,796 Fair value of the common stock issued 2,311 Transaction costs 165 Total consideration $ 4,272

Composition of Certain Financia

Composition of Certain Financial Statement Captions	12 Months Ended
	Dec. 31, 2017
Composition Of Certain Financial Statement Captions [Abstract]
Composition of Certain Financial Statement Captions	6. Composition of Certain Financial Statement Captions Inventories, net As of December 31, 2017 and 2016, inventories, net, were comprised of the following (in thousands): December 31, 2017 2016 Raw materials $ 681 $ 885 Work in process 722 1,021 Finished goods 1,780 1,819 $ 3,183 $ 3,725 Other Current Assets As of December 31, 2017 and 2016, other current assets were comprised of the following (in thousands): December 31, 2017 2016 Prepaid supplies or services, current $ 544 $ 734 Prepaid insurance 556 83 Prepaid consumption tax in Japan 99 2 Other receivables 112 51 $ 1,311 $ 870 Property and Equipment, net As of December 31, 2017 and 2016, property and equipment, net, were comprised of the following (in thousands): December 31, 2017 2016 Manufacturing and development equipment $ 4,507 $ 4,256 Office and computer equipment 1,805 1,953 Leasehold improvements 5,087 3,399 11,399 9,608 Less accumulated depreciation (8,347 ) (8,451 ) $ 3,052 $ 1,157 Depreciation expense totaled $0.9 million and $0.7 million for the years ended December 31, 2017 and 2016, respectively. Other Assets As of December 31, 2017 and 2016, other assets were comprised of the following (in thousands): December 31, 2017 2016 Prepaid supplies, long-term $ 2,181 $ 1,838 Deposits 389 498 $ 2,570 $ 2,336 Accounts Payable and Accrued Expenses As of December 31, 2017 and 2016, accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2017 2016 Accrued expenses $ 1,599 $ 1,752 Accounts payable 1,297 1,332 Accrued payroll and bonus 810 989 Accrued legal fees 509 614 Accrued vacation 64 502 Accrued R&D studies 286 347 Other current liabilities 225 336 $ 4,790 $ 5,872

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December 31, 2017, we have clinical research study obligations of $0.6 million, all of which are expected to be complete within a year. Should the timing of the clinical trials change, the timing of the payment of these obligations would also change. We lease facilities for our headquarters office location as well as international office locations. As of December 31, 2017, we have contractual lease obligations to make payments on leases of office and manufacturing space as follows: Years Ending December 31, Obligation 2018 $ 589 2019 565 2020 541 2021 541 2022 138 Total $ 2,374 Rent expense, which includes common area maintenance, for the years ended December 31, 2017 and 2016 was $2.2 million and $2.5 million, respectively. On February 27, 2017, we entered into a Lease Agreement of office space for our corporate headquarters in San Diego, California (the “Lease”). The initial term of the Lease is 63 months and may be extended upon mutual agreement. The commencement date was originally expected to take place in November 2017 and subsequently amended to January 1, 2018. In connection with our restructuring announced in September 2017, we began negotiations with the landlord and in February 2018, announced a buy-out of our obligations with the Lease of approximately $0.6 million. On January 27, 2017, we entered into a Lease Agreement of office space for our office in Tokyo, Japan (the “Japan Lease”). The initial term of the Japan Lease is 61 months, and may be extended upon mutual agreement. The Lease commenced on April 15, 2017. We are party to an agreement with Roche Diagnostics Corporation, our sole supplier of reagents, which requires us to make certain product purchase minimums until 2020. Pursuant to the agreement, as of December 31, 2017, we have a minimum purchase obligation as follows: Years Ending December 31, Obligation 2018 $ 1,074 2019 1,473 2020 1,473 Total $ 4,020 We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.

Long-term Obligations

Long-term Obligations	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-term Obligations	8. Long-term Obligations On May 29, 2015, we entered into the Loan and Security Agreement, (the “Loan and Security Agreement”), with Oxford, pursuant to which Oxford funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, we were previously required to make interest only payments through June 1, 2016 and thereafter we were required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2019, the maturity date. On February 23, 2016, we received an acknowledgement and agreement from Oxford related to the positive data on our U.S. ACT-OA clinical trial. As a result, pursuant to the Loan and Security Agreement, the period for which we are required to make interest-only payments was extended from July 1, 2016 to January 1, 2017. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, we are required to make a final payment in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to Oxford warrants to purchase an aggregate of 94,441 shares of our common stock at an exercise price of $10.35 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt. On September 20, 2017, we entered into an amendment to the Term Loan, pursuant to which, among other things, Oxford and the Lenders agreed to reduce the minimum The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving certain liquidity level when the total principal outstanding under the Loan Agreement is less than $3 million. The Term Loan Agreement contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by us or a declaration of material adverse change by our lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Term Loan, which could materially harm our financial condition. As of December 31, 2017, we were in compliance with all covenants under the Term Loan and have not received any notification or indication from the Lenders to invoke the material adverse change clause. However, due to our current cash flow position and the substantial doubt about our ability to continue as a going concern, the entire principal amount of the Term Loan has been reclassified to short-term. We will continue to evaluate the debt classification on a quarterly basis and evaluate for reclassification in the future should our financial condition improve. Additional details relating to the outstanding Term Loan as of December 31, 2017 and 2016 are presented in the following table (in thousands): Year ended December 31, 2017 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment*** Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 100 48 Months $ 12,980 Year ended December 31, 2016 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment* Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 136 48 Months $ 17,700 * ** *** As of December 31, 2017, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2018 $ 5,192 2019 8,877 Total $ 14,069 Reconciliation of Face Value to Book Value as of December 31, 2017 Total debt and lease obligations, including final payment fee (Face Value) $ 14,069 Less: Debt discount (445 ) Total obligation $ 13,624 Our interest expense for the years ended December 31, 2017 and 2016 was $2.0 million and $2.6 million, respectively. Interest expense is calculated using the effective interest method, therefore it is inclusive of non-cash amortization in the amount of $0.7 million and $1.0 million, respectively, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes Due to our net losses for the years ended December 31, 2017 and 2016, and since we have recorded a full valuation allowance against deferred tax assets, there was no provision or benefit for income taxes recorded. The components of income/(loss) before income tax provision (benefit) as of December 31, 2017 and 2016 are as follows (in thousands): 2017 2016 U.S. $ (21,915) $ (20,387) Foreign (771) (1,659) $ (22,686) $ (22,046) A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 34% for the years ended December 31, 2017 and 2016 is as follows: 2017 2016 Income tax expense (benefit) at federal statutory rate (34.0 )% (34.0 )% Income tax expense (benefit) at state statutory rate (3.9 )% (3.4 )% Change in valuation allowance (172.4 )% 16.8 % Change in state rate (0.8 )% (0.1 )% Permanent interest adjustments 0.2 % 0.2 % Stock compensation 3.0 % 12.7 % Research credit (1.1 )% (1.4 )% Foreign rate differential 202.1 % 0.8 % NOLs expiring and adjustments to NOL 7.0 % 6.0 % Other, net (0.2 )% 2.5 % (0.0 )% 0.0 % The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are as follows (in thousands): 2017 2016 Deferred tax assets: Allowances and reserves $ 140 $ 573 Accrued expenses 154 701 Stock based compensation 1,065 1,947 Net operating loss carryforwards 87,426 125,182 Income tax credit carryforwards 8,587 7,764 Property and equipment, principally due to differences in depreciation 514 675 Other, net 45 48 97,931 136,890 Valuation allowance (97,089 ) (134,873 ) Total deferred tax assets, net of allowance 842 2,017 Deferred tax liabilities: Intangibles assets (842 ) (2,017 ) Total deferred tax liability (842 ) (2,017 ) Net deferred tax assets (liability) $ — $ — We have established a valuation allowance against our net deferred tax assets due to the uncertainty surrounding the realization of such assets. We periodically evaluate the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. We have recorded a full valuation allowance of $97.1 million as of December 31, 2017 as we do not believe it is more likely than not our net deferred tax assets will be realized. We decreased our valuation allowance by approximately $37.8 million during the year ended December 31, 2017. At December 31, 2017, we had federal, and state tax loss carry forwards of approximately $365.9 million, and $147.4 million. The federal and state net operating loss carry forwards begin to expire in 2019 and 2028, respectively, if unused. At December 31, 2017, we had federal and state tax credit carry forwards of approximately $5.1 million and $4.5 million, respectively, after reduction for uncertain tax positions. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2018, if unused, and the state credits carry forward indefinitely. Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC §382 and IRC §383, our ability to use net operating loss and R&D tax credit carry forwards (“tax attribute carry forwards”) to offset future taxable income is limited if we experience a cumulative change in ownership of more than 50% within a three-year testing period. We have not completed an ownership change analysis pursuant to IRC Section 382 for taxable years ended after December 31, 2007. If ownership changes within the meaning of IRC Section 382 are identified as having occurred subsequent to 2007, the amount of remaining tax attribute carry forwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, our deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC §382. In December 2017, the Tax Cuts and Jobs Act (the "2017 Act) was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017. The 2017 Act also provides for a one-time transition tax on certain foreign earnings and the acceleration of depreciation for certain assets placed in service after September 27, 2017, as well as, prospective changes beginning in 2018, including additional limitations on executive compensation, limitations on the deductibility of interest and capitalization of research and development expenditures. While the 2017 Act provides for a territorial tax system, beginning in 2018, it includes two new U.S. tax base erosion provision, the global intangible low-taxed income ("GILTI") provisions and the base-erosion and anti-abuse tax ("BEAT") provisions. Reduction of the U.S. Corporate Income Tax Rate: The Company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, the Company's deferred tax assets and liabilities were premeasured to reflect the reduction in the U.S. corporate income tax rate from 35 percent to 21 percent, resulting in a $45.8 million increase in tax expense for the year ended December 31, 2017 and a corresponding $(45.8) million decrease in net deferred tax assets as of December 31, 2017. The impact was fully offset by a valuation allowance. The Act will no longer allow deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance based compensation. It also subjects the principal executive officer, principal financial officer and three other highest paid officers to the limitation and once the individual becomes a covered person, the individual will remain a covered person for all future years. The tax effects of these provisions require further analysis which is expected to be completed in the second half of 2018. The 2017 Act provided for a one-time deemed mandatory repatriation of post-1986 undistributed foreign subsidiary earnings and profits ("E&P") through the year ended December 31, 2017. The Company's foreign subsidiary had an estimated accumulated deficit as of December 31, 2017. The Company does not expect it will be subject to this tax and therefore has not included any tax impacts related to the mandatory deemed repatriation in its consolidated financial statements. The GILTI provisions require the Company to include in its US income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary's tangible assets. While the Company may elect to account for GILTI tax in the period in which it is incurred, or recognize deferred taxes when basis differences exist that are expected to affect the amount of the GILTI inclusion upon reversal, the Company has not yet completed a detailed analysis of the GILTI and has not made a policy election as of December 31, 2017 The BEAT provisions in the 2017 Act eliminates the deduction of certain base-erosion payments made to foreign corporations, and impose a minimum tax if greater than regular tax. The Company does not expect it will be subject to this tax and does not anticipate any tax impacts of BEAT with the filing of its consolidated financial statements for 2017. On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Act. The Company has recognized provisional tax impacts related to the revaluation of deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017. The ultimate impact may differ from these provisional amounts due to among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the 2017 Act. The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018. The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has not recognized any liability for uncertain tax positions as of December 31, 2017 and 2016. Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2017 and 2016 (in thousands): 2017 2016 Unrecognized Tax Benefits – Beginning $ 2,062 $ 1,987 Gross increases – tax positions in prior period — 1 Gross decreases – tax positions in prior period — (13 ) Gross increase – current-period tax positions 95 87 Unrecognized Tax Benefits – Ending $ 2,157 $ 2,062 The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months. The Company did not recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses as of December 31, 2017. The Company’s material tax jurisdictions are United States and California. To its knowledge, the Company is currently not under examination by the Internal Revenue Service or any other taxing authority. The Company’s tax years for 1998 (federal) and 1997 (CA) and forward can be subject to examination by the United States and California tax authorities due to the carry forward of net operating losses and research development credits.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	10. Employee Benefit Plan We implemented a 401(k) retirement savings and profit sharing plan (the “Plan”) effective January 1, 1999. We may make discretionary annual contributions to the Plan, which is allocated to the profit sharing accounts based on the number of years of employee service and compensation. At the sole discretion of the Board of Directors, we may also match the participants’ contributions to the Plan. We made no discretionary or matching contributions to the Plan in 2017 or 2016.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity	11. Stockholders’ Equity Preferred Stock The Company has authorized 5 million shares of preferred stock, par value $0.001 per share. The Company’s Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock that had been issued at December 31, 2017 and 2016, none of which were outstanding as of either date. All outstanding shares of the Series A 3.6% Convertible Preferred Stock were converted into common stock by the first quarter of 2015 at the option of the holders. On November 27, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the “Series B Convertible Preferred Stock”. The number of shares initially constituting the Series B Convertible Preferred Stock was set at 10,000 shares. Pursuant to a registration statement on Form S-1, originally filed on August 14, 2017, as amended, and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on November 2, 2017, and related prospectus (as supplemented), the Company registered and distributed to holders of its common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 10,000 units consisting of 10,000 shares of Series B Convertible Preferred Stock and 18 million warrants, with each warrant exercisable for one common stock at an exercise price of $0.3333 per share for 30 months from the date of issuance at any time after the date the stockholder approval to increase our authorized common stock share count. Pursuant to the 2017 Rights Offering, which closed on November 28, 2017, the Company sold an aggregate of 10,000 units, resulting in total net proceeds to the Company of approximately $8.8 million. . Based on the relevant authoritative accounting guidance, the warrants were equity classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $0.833 per share for 10 consecutive trading days. The fair value of the common stock into which the Series B Convertible Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. We recorded a deemed dividend within additional paid-in capital of $4.0 million for the year ended December 31, 2017, related to a beneficial conversion feature included in the issuance of our Series B Convertible Preferred Stock. Approximately 75% of the of the outstanding shares of the Series B Convertible Preferred Stock were converted into common stock by December 31, 2017 at the option of the holders. Common Stock Pursuant to a registration statement on Form S-1, originally filed on April 6, 2016, as amended, and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on May 26, 2016, and related prospectus (as supplemented), the Company registered and distributed to its participating stockholders of record as of the announced May 20, 2016 record date, one non-transferable subscription right for each share of common stock held by each stockholder as of the record date (“2016 Rights Offering”). Each right entitled the holder thereof to purchase one unit at the subscription price of $2.55 per unit, composed of one share of common stock and 0.5 of a warrant, with each whole warrant exercisable to purchase one share of common stock at an exercise price of $3.06 per share for 30 months from the date of issuance. Pursuant to the 2016 Rights Offering, which closed on June 15, 2016, the Company sold an aggregate of 6,704,852 units, resulting in total net proceeds to the Company of $15.3 million. The warrants issued pursuant to the 2016 Rights Offering are currently listed on Nasdaq under the symbol “CYTXW.” Based on the relevant authoritative accounting guidance, the warrants were equity classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $7.65 per share for 10 consecutive trading days. On December 22, 2016, the Company entered into a Purchase Agreement (the “Lincoln Park Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million in amounts of shares, of the Company’s common stock, over the 30-month period following March 30, 207. The Company may direct Lincoln Park, at the Company’s sole discretion and subject to certain conditions, to purchase up to 100,000 shares of common stock on any business day but in no event will the amount of a single Regular Purchase (as defined in the Lincoln Park Purchase Agreement) exceed $1.0 million. The purchase price of shares of common stock related to the Regular Purchases will be based on the prevailing market prices of such shares at the time of sales. The Company’s sales of shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of the common stock. There are no trading volume requirements or restrictions under the Lincoln Park Purchase Agreement. There is no upper limit on the price per share that Lincoln Park must pay for common stock under a Regular Purchase or an accelerated purchase and in no event will shares be sold to Lincoln Park on a day our closing price is less than the floor price of $0.50 per share as set forth in the Purchase Agreement. On December 22, 2016, the Company issued to Lincoln Park 127,419 shares of common stock with a market value on the date of issuance of approximately $0.2 million as commitment shares in consideration for entering into the Lincoln Park Purchase Agreement. The Company will issue up to an additional 382,258 shares of common stock on a pro rata basis to Lincoln Park only as and when shares are sold under the Lincoln Park Purchase Agreement to Lincoln Park. Through December 31, 2017, the Company has sold a total of 1.9 million shares under the Lincoln Park Purchase Agreement, for proceeds of approximately $1.7 million.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	12. Stock-based Compensation In August 2014, we adopted the 2014 Equity Incentive Plan (the “2014 Plan”), which provides our employees, directors and consultants the opportunity to purchase our common stock in the form of options (incentive or non-qualified), stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards other stock-based awards, and deferred compensation awards. The 2014 Plan initially provides for issuance of 265,000 shares of our common stock. In August 2015, the Company amended the 2014 Plan to add 301,800 shares to its share pool. In addition, the amendment increased the number of “incentive stock options” which may be issued under the 2014 Plan by an identical amount. In May 2016, the Company amended the 2014 Plan to add 333,333 shares to its share pool. In May 2017, the Company amended the 2014 Plan to add 2,000,000 shares to its share pool. On December 29, 2015, we adopted the 2015 New Employee Incentive Plan (the “2015 Plan”). Awards under the 2015 Plan may only be made to an employee who has not previously been an employee or member of the Board of any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The 2015 Plan provides for issuance of 66,666 shares. In January 2017, the Company amended the 2015 Plan to add 250,000 shares to its share pool. As of December 31, 2017, there are 304,166 shares and 2,060,504 shares of common stock remaining and available for future issuances under the 2015 and 2014 Plans, respectively, which are exclusive of securities to be issued upon an exercise of outstanding options, warrants, and rights. Stock Options Generally, options issued under the 2014 Plan, are subject to four-year vesting, and have a contractual term of 10 years. Most options contain one of the following two vesting provisions: • 12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or • 1/48 of the award will vest at the end of each month over a four-year period. A summary of activity for the year ended December 31, 2017 is as follows: Options Weighted Average Exercise Price Balance as of January 1, 2017 636,112 $ 24.39 Granted 710,600 $ 1.47 Expired (19,450 ) $ 82.46 Cancelled/forfeited (316,944 ) $ 9.06 Balance as of December 31, 2017 1,010,318 $ 11.96 Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance as of December 31, 2017 1,010,318 $ 11.96 7.95 $ — Vested and expected to vest at December 31, 2017 893,185 $ 13.35 7.80 $ — Exercisable at December 31, 2017 401,599 $ 26.89 6.45 $ — There were no stock options exercised in 2017 or 2016. The fair value of each option awarded during the year ended December 31, 2017 and 2016 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: Years ended December 31, 2017 2016 Expected term 6.6 years 6.0 years Risk-free interest rate 2.20 % 1.75 % Volatility 78.84 % 77.56 % Dividends — — Resulting weighted average grant date fair value $ 1.05 $ 1.84 The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, we use the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. The dividend yield has been assumed to be zero as we (a) have never declared or paid any dividends and (b) do not currently anticipate paying any cash dividends on our outstanding shares of common stock in the foreseeable future. Restricted Stock Awards Generally, restricted stock awards issued under the 2014 Plan are subject to a vesting period that coincides with the fulfillment of service requirements for each award and have a contractual term of 10 years. These awards are amortized to compensation expense over the estimated vesting period based upon the fair value of our common stock on the award date. The following summarizes the total compensation cost recognized for the stock options and restricted stock awards in the accompanying financial statements (in thousands): Years ended December 31, 2017 2016 Total compensation cost for share-based payment arrangements recognized in the statement of operations $ 753 $ 1,080 As of December 31, 2017, the total compensation cost related to non-vested stock options and stock awards not yet recognized for all our plans is approximately $0.6 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 1.5 years. To settle stock options and restricted stock awards, we will issue new shares of our common stock. At December 31, 2017, we have an aggregate of 6,208,390 shares authorized and available to satisfy option exercises under our plans.

Quarterly Information (unaudite

Quarterly Information (unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Information (unaudited)	13. Quarterly Information (unaudited) The following unaudited quarterly financial information includes, in management’s opinion, all the normal and recurring adjustments necessary to fairly state the results of operations and related information for the periods presented (in thousands): For the three months ended March 31, 2017 June 30, 2017 September 30, 2017 December 31, 2017 Product revenues $ 591 $ 969 $ 467 $ 662 Gross profit (125 ) 262 (20 ) 29 Development revenues 1,018 531 1,306 867 Operating expenses (6,336 ) (6,374 ) (5,629 ) (4,526 ) In process research and development acquired from Azaya (1,686 ) — — — Other expense, net (415 ) (468 ) (464 ) (656 ) Net income (loss) $ (7,544 ) $ (6,049 ) $ (4,807 ) $ (4,286 ) Beneficial conversion feature for convertible preferred stock — — — (3,977 ) Net income (loss) allocable to common stock holders (7,544 ) (6,049 ) (4,807 ) (8,263 ) Basic and diluted net loss per share $ (0.33 ) $ (0.19 ) $ (0.14 ) $ (0.20 ) For the three months ended March 31, 2016 June 30, 2016 September 30, 2016 December 31, 2016 Product revenues $ 1,333 $ 1,126 $ 731 $ 1,466 Gross profit 766 541 113 521 Development revenues 1,585 1,699 1,879 1,561 Operating expenses (7,448 ) (8,464 ) (6,789 ) (5,670 ) Other expense, net (242 ) (181 ) (587 ) (1,330 ) Net income (loss) $ (5,339 ) $ (6,405 ) $ (5,384 ) $ (4,918 ) Beneficial conversion feature for convertible preferred stock — — — — Net income (loss) allocable to common stock holders (5,339 ) (6,405 ) (5,384 ) (4,918 ) Basic and diluted net loss per share $ (0.41 ) $ (0.43 ) $ (0.26 ) $ (0.24 )

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2017
Valuation And Qualifying Accounts [Abstract]
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	(a) (2) Financial Statement Schedules SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the years ended December 31, 2017 and 2016 (in thousands) Balance at beginning of year Additions (A) Deductions (B) Other (C) Balance at end of year Allowance for doubtful accounts Year ended December 31, 2017 $ 167 $ — $ — $ — $ 167 Year ended December 31, 2016 $ 797 $ — $ (630 ) $ — $ 167 (A) Includes charges to costs and expenses. (B) Deductions for uncollectible accounts receivable includes payments collected and devices recovered from customers. (C) Miscellaneous activity.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring expense related to our in-process research and development acquisition, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Cash and cash equivalents	Cash and cash equivalents We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents includes cash in readily available checking and savings accounts. We held no investments as of December 31, 2017 and 2016. We maintain our cash at insured financial institutions.
Restricted Cash	Restricted Cash Restricted cash consists of cash invested in certificate of deposits used as collateral for the issuance of letters of credit pursuant to lease agreements for leasing of property at 3020 and 3030 Callan Road, San Diego, CA, which requires us to execute a letter of credit for $0.2 million naming the landlord as a beneficiary as of December 31, 2017. In addition, in connection with the new lease (see Note 7) we executed in 2017, we issued a letter of credit in favor of that landlord in the amount of $0.5 million, which will remain in effect for the term of the lease.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company periodically assesses the collectability of accounts receivable on a specific customer basis considering factors such as evaluation of collectability, historical collection experience, the age of accounts receivable and other currently available evidence of the collectability, and records an allowance for doubtful accounts for the estimated uncollectible amount. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Inventories	Inventories Inventories include the cost of material, labor, and overhead related to Celution devices, consumable kits, and reagents, and are stated at the lower of cost, determined on the first-in, first-out (FIFO) method, or net realizable value. We periodically evaluate our on-hand stock and make appropriate provisions for any stock deemed excess or obsolete. Manufacturing costs resulting from lower than “normal” production levels are expensed as incurred.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred.
Impairment	Impairment We assess certain of our long-lived assets, such as property and equipment and intangible assets other than goodwill, for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. We recognized no impairment losses during any of the periods presented in these financial statements.
Goodwill and Intangibles	Goodwill and Intangibles Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, there is an indication that goodwill may be impaired and the amount of the loss, if any, is measured by performing step two. Under step two, the impairment loss, if any, is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. There was no indication of impairment of goodwill for all periods presented. Separable intangible assets that have finite useful lives are amortized over their respective useful lives. As part of the May 2013 acquisition of the Joint Venture (see Note 3), we acquired intangible assets which consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. The technology was valued at $9.4 million and is being amortized on a straight-line basis over a useful life of eleven years, commensurate with the expected cash flows. The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2017 and 2016 are as follows (in thousands): December 31, 2017 December 31, 2016 Intangibles, net: Beginning balance $ 8,447 $ 9,031 Increase — — Amortization (1,240 ) (584 ) Ending balance 7,207 8,447 Goodwill, net: Beginning balance 3,922 3,922 Increase (decrease) — — Ending balance 3,922 3,922 Total goodwill and other intangibles, net $ 11,129 $ 12,369
Revenue Recognition	Revenue Recognition Product Sales We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We evaluate customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction and defer revenues until collectability is reasonably assured. For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books. Concentration of Significant Customers & Geographical Sales For the year ended December 31, 2017, our sales were concentrated with respect to five direct customers, which comprised 68% of our product revenue recognized. One licensee and one direct customer accounted for 77% of total outstanding accounts For the year ended December 31, 2016, our sales were concentrated with respect to two distributors and three direct customers, which comprised 65% of our product revenue recognized. Two direct customers accounted for 57% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2016. Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2017 2016 Product Revenues % of Total Product Revenues % of Total Americas $ 345 13 % $ 936 20 % Japan 1,924 71 % 3,279 71 % EMEA 344 13 % 379 8 % Asia Pacific 76 3 % 62 1 % Total product revenues $ 2,689 100 % $ 4,656 100 % Development Revenues We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $3.7 million and $6.7 million in BARDA revenue for the years ended December 31, 2017 and 2016, respectively.
Research and Development	Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for our research and development employees. Also included in research and development expenditures are costs incurred to support the government reimbursement contract, including $3.5 million and $6.3 million of qualified expenses that were incurred for the years ended December 31, 2017 and 2016, related to our government contract with BARDA.
Deferred Financing Costs and Other Debt-Related Costs	Deferred Financing Costs and Other Debt-Related Costs Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2017 and 2016, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months.
Share-Based Compensation	Share-Based Compensation We recognize the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the award. We estimate the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and applied to all employee awards as a single group as we do not expect (nor does historical data suggest) substantially different exercise or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term.
Segment Information	Segment Information For the years ended December 31, 2017 and 2016, the Company is managed as a single operating segment, therefore we report our results in one operating segment.
Loss Per Share	Loss Per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the years ended December 31, 2017 and 2016, as their inclusion would be antidilutive. Potentially dilutive securities excluded from the calculations of diluted loss per share were 20.5 million as of December 31, 2017, which includes 19.5 million outstanding warrants and 1.0 million options and restricted stock awards. Potentially dilutive securities excluded from the calculations of diluted loss per share were 4.2 million as of December 31, 2016.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. We will adopt the standards beginning the first quarter of 2018 using the modified retrospective method. We have completed our assessment of the new standard and are evaluating the impact of the new required disclosures. Overall, we do not expect the timing or amounts related to the revenue recognition under the new standards to be materially different from our current revenue recognition policy. Our product revenues are recognized at a point in time, which is when we control transfers to the customer. We will make accounting policy elections to 1) treat shipping and handling activities that occur after the customer obtains control of the goods as fulfillment costs and 2) exclude sales (and similar) taxes from the measurement of the transaction price. Because we have no open contracts as of December 31, 2017, there will be no cumulative effect of applying the new standards. In February 2016, the FASB issued ASU 2016-02, Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of certain cash receipts and cash payments In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation Recently Adopted Accounting Pronouncements In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Intangible Assets and Goodwill	The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2017 and 2016 are as follows (in thousands): December 31, 2017 December 31, 2016 Intangibles, net: Beginning balance $ 8,447 $ 9,031 Increase — — Amortization (1,240 ) (584 ) Ending balance 7,207 8,447 Goodwill, net: Beginning balance 3,922 3,922 Increase (decrease) — — Ending balance 3,922 3,922 Total goodwill and other intangibles, net $ 11,129 $ 12,369
Product Revenues, Classified by Geographic Location	Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2017 2016 Product Revenues % of Total Product Revenues % of Total Americas $ 345 13 % $ 936 20 % Japan 1,924 71 % 3,279 71 % EMEA 344 13 % 379 8 % Asia Pacific 76 3 % 62 1 % Total product revenues $ 2,689 100 % $ 4,656 100 %

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value and Carrying Value of Long-term Debt	At December 31, 2017 and 2016, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows (in thousands): December 31, 2017 December 31, 2016 Fair Value Carrying Value Fair Value Carrying Value Debt $ 13,427 $ 13,624 $ 17,611 $ 17,637

Asset Purchase Agreement with24

Asset Purchase Agreement with Azaya Therapeutics (Table)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Summery of Purchase Price Allocation on Fair Value Basis to Identifiable Net Assets	The total consideration was allocated on a relative fair value basis to the assets acquired, as follows (in thousands): February 15, 2017 Tangible assets $ 2,586 Intangible assets 1,686 Total assets $ 4,272 Accounts payable $ 1,796 Fair value of the common stock issued 2,311 Transaction costs 165 Total consideration $ 4,272

Composition of Certain Financ25

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Dec. 31, 2017
Composition Of Certain Financial Statement Captions [Abstract]
Inventories, net	Inventories, net As of December 31, 2017 and 2016, inventories, net, were comprised of the following (in thousands): December 31, 2017 2016 Raw materials $ 681 $ 885 Work in process 722 1,021 Finished goods 1,780 1,819 $ 3,183 $ 3,725
Other Current Assets	Other Current Assets As of December 31, 2017 and 2016, other current assets were comprised of the following (in thousands): December 31, 2017 2016 Prepaid supplies or services, current $ 544 $ 734 Prepaid insurance 556 83 Prepaid consumption tax in Japan 99 2 Other receivables 112 51 $ 1,311 $ 870
Property and Equipment, net	Property and Equipment, net As of December 31, 2017 and 2016, property and equipment, net, were comprised of the following (in thousands): December 31, 2017 2016 Manufacturing and development equipment $ 4,507 $ 4,256 Office and computer equipment 1,805 1,953 Leasehold improvements 5,087 3,399 11,399 9,608 Less accumulated depreciation (8,347 ) (8,451 ) $ 3,052 $ 1,157
Other Assets	Other Assets As of December 31, 2017 and 2016, other assets were comprised of the following (in thousands): December 31, 2017 2016 Prepaid supplies, long-term $ 2,181 $ 1,838 Deposits 389 498 $ 2,570 $ 2,336
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses As of December 31, 2017 and 2016, accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2017 2016 Accrued expenses $ 1,599 $ 1,752 Accounts payable 1,297 1,332 Accrued payroll and bonus 810 989 Accrued legal fees 509 614 Accrued vacation 64 502 Accrued R&D studies 286 347 Other current liabilities 225 336 $ 4,790 $ 5,872

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Future Minimum Debt and Lease Payments	As of December 31, 2017, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2018 $ 5,192 2019 8,877 Total $ 14,069
Minimum Purchase Obligation	Pursuant to the agreement, as of December 31, 2017, we have a minimum purchase obligation as follows: Years Ending December 31, Obligation 2018 $ 1,074 2019 1,473 2020 1,473 Total $ 4,020
Payment on Lease Office and Manufacturing Space [Member]
Future Minimum Debt and Lease Payments	As of December 31, 2017, we have contractual lease obligations to make payments on leases of office and manufacturing space as follows: Years Ending December 31, Obligation 2018 $ 589 2019 565 2020 541 2021 541 2022 138 Total $ 2,374

Long-term Obligations (Tables)

Long-term Obligations (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Term Loan Outstanding	Additional details relating to the outstanding Term Loan as of December 31, 2017 and 2016 are presented in the following table (in thousands): Year ended December 31, 2017 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment*** Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 100 48 Months $ 12,980 Year ended December 31, 2016 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment* Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 136 48 Months $ 17,700 * ** ***
Future Minimum Debt and Lease Payments	As of December 31, 2017, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2018 $ 5,192 2019 8,877 Total $ 14,069
Face Value to Book Value Reconciliation	Reconciliation of Face Value to Book Value as of December 31, 2017 Total debt and lease obligations, including final payment fee (Face Value) $ 14,069 Less: Debt discount (445 ) Total obligation $ 13,624

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of Income/(Loss) Before Income Tax Provision (Benefit)	The components of income/(loss) before income tax provision (benefit) as of December 31, 2017 and 2016 are as follows (in thousands): 2017 2016 U.S. $ (21,915) $ (20,387) Foreign (771) (1,659) $ (22,686) $ (22,046)
Reconciliation of Total Income Tax Provision	A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 34% for the years ended December 31, 2017 and 2016 is as follows: 2017 2016 Income tax expense (benefit) at federal statutory rate (34.0 )% (34.0 )% Income tax expense (benefit) at state statutory rate (3.9 )% (3.4 )% Change in valuation allowance (172.4 )% 16.8 % Change in state rate (0.8 )% (0.1 )% Permanent interest adjustments 0.2 % 0.2 % Stock compensation 3.0 % 12.7 % Research credit (1.1 )% (1.4 )% Foreign rate differential 202.1 % 0.8 % NOLs expiring and adjustments to NOL 7.0 % 6.0 % Other, net (0.2 )% 2.5 % (0.0 )% 0.0 %
Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are as follows (in thousands): 2017 2016 Deferred tax assets: Allowances and reserves $ 140 $ 573 Accrued expenses 154 701 Stock based compensation 1,065 1,947 Net operating loss carryforwards 87,426 125,182 Income tax credit carryforwards 8,587 7,764 Property and equipment, principally due to differences in depreciation 514 675 Other, net 45 48 97,931 136,890 Valuation allowance (97,089 ) (134,873 ) Total deferred tax assets, net of allowance 842 2,017 Deferred tax liabilities: Intangibles assets (842 ) (2,017 ) Total deferred tax liability (842 ) (2,017 ) Net deferred tax assets (liability) $ — $ —
Unrecognized Tax Benefits Activity	Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2017 and 2016 (in thousands): 2017 2016 Unrecognized Tax Benefits – Beginning $ 2,062 $ 1,987 Gross increases – tax positions in prior period — 1 Gross decreases – tax positions in prior period — (13 ) Gross increase – current-period tax positions 95 87 Unrecognized Tax Benefits – Ending $ 2,157 $ 2,062

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	A summary of activity for the year ended December 31, 2017 is as follows: Options Weighted Average Exercise Price Balance as of January 1, 2017 636,112 $ 24.39 Granted 710,600 $ 1.47 Expired (19,450 ) $ 82.46 Cancelled/forfeited (316,944 ) $ 9.06 Balance as of December 31, 2017 1,010,318 $ 11.96
Stock Options Vested and Expected to Vest	Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance as of December 31, 2017 1,010,318 $ 11.96 7.95 $ — Vested and expected to vest at December 31, 2017 893,185 $ 13.35 7.80 $ — Exercisable at December 31, 2017 401,599 $ 26.89 6.45 $ —
Weighted-average Assumptions	The fair value of each option awarded during the year ended December 31, 2017 and 2016 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: Years ended December 31, 2017 2016 Expected term 6.6 years 6.0 years Risk-free interest rate 2.20 % 1.75 % Volatility 78.84 % 77.56 % Dividends — — Resulting weighted average grant date fair value $ 1.05 $ 1.84
Compensation Cost Recognized for Stock Options and Restricted Stock Awards	The following summarizes the total compensation cost recognized for the stock options and restricted stock awards in the accompanying financial statements (in thousands): Years ended December 31, 2017 2016 Total compensation cost for share-based payment arrangements recognized in the statement of operations $ 753 $ 1,080

Quarterly Information (unaudi30

Quarterly Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Unaudited Quarterly Financial Information	The following unaudited quarterly financial information includes, in management’s opinion, all the normal and recurring adjustments necessary to fairly state the results of operations and related information for the periods presented (in thousands): For the three months ended March 31, 2017 June 30, 2017 September 30, 2017 December 31, 2017 Product revenues $ 591 $ 969 $ 467 $ 662 Gross profit (125 ) 262 (20 ) 29 Development revenues 1,018 531 1,306 867 Operating expenses (6,336 ) (6,374 ) (5,629 ) (4,526 ) In process research and development acquired from Azaya (1,686 ) — — — Other expense, net (415 ) (468 ) (464 ) (656 ) Net income (loss) $ (7,544 ) $ (6,049 ) $ (4,807 ) $ (4,286 ) Beneficial conversion feature for convertible preferred stock — — — (3,977 ) Net income (loss) allocable to common stock holders (7,544 ) (6,049 ) (4,807 ) (8,263 ) Basic and diluted net loss per share $ (0.33 ) $ (0.19 ) $ (0.14 ) $ (0.20 ) For the three months ended March 31, 2016 June 30, 2016 September 30, 2016 December 31, 2016 Product revenues $ 1,333 $ 1,126 $ 731 $ 1,466 Gross profit 766 541 113 521 Development revenues 1,585 1,699 1,879 1,561 Operating expenses (7,448 ) (8,464 ) (6,789 ) (5,670 ) Other expense, net (242 ) (181 ) (587 ) (1,330 ) Net income (loss) $ (5,339 ) $ (6,405 ) $ (5,384 ) $ (4,918 ) Beneficial conversion feature for convertible preferred stock — — — — Net income (loss) allocable to common stock holders (5,339 ) (6,405 ) (5,384 ) (4,918 ) Basic and diluted net loss per share $ (0.41 ) $ (0.43 ) $ (0.26 ) $ (0.24 )

Organization and Operations - A

Organization and Operations - Additional Information (Details)	Nov. 28, 2017USD ($)$ / sharesshares	Sep. 05, 2017$ / shares	May 31, 2017USD ($)$ / sharesshares	Apr. 11, 2017USD ($)$ / sharesshares	Dec. 22, 2016USD ($)	Jun. 16, 2016USD ($)shares	May 10, 2016shares	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)Subsidiary$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Jun. 15, 2016$ / sharesshares	May 11, 2016shares	Dec. 31, 2015USD ($)shares
Basis Of Presentation And New Accounting Standards [Line Items]
Number of wholly-owned subsidiaries | Subsidiary																5
Reverse stock split of common stock							15
Common stock, shares outstanding (in shares)							200,000,000	57,825,729				21,707,890				57,825,729	21,707,890		13,300,000
Number of shares callable by warrants (in shares)							16,000,000											1	1,100,000
Common stock, shares authorized (in shares)							290,000,000	75,000,000				75,000,000				75,000,000	75,000,000		75,000,000
Net loss | $								$ 4,286,000	$ 4,807,000	$ 6,049,000	$ 7,544,000	$ 4,918,000	$ 5,384,000	$ 6,405,000	$ 5,339,000	$ 22,686,000	$ 22,046,000
Accumulated deficit | $								(401,749,000)				(379,063,000)				(401,749,000)	(379,063,000)
Net cash used in operating activities | $																$ (18,128,000)	(19,533,000)
Substantial doubt about going concern, description																The Company does not have sufficient capital to fund operations through one year from the issuance date of these consolidated financial statements. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
Cash and cash equivalents | $								9,550,000				$ 12,560,000				$ 9,550,000	12,560,000			$ 14,338,000
Minimum cash/cash equivalents covenant | $								$ 1,500,000								1,500,000
Common stock issued (in shares)	10,000					6,704,852
Each unit consist of number of warrant						3,352,306
Warrant exercise price (in dollars per share) | $ / shares																		$ 3.06
Proceeds from issuance warrants | $	$ 8,800,000					$ 17,100,000
Common stock issued, value | $																$ 12,716,000	$ 19,478,000
Common stock, par value (in dollars per share) | $ / shares								$ 0.001				$ 0.001				$ 0.001	$ 0.001
Proceeds from sale of common stock, net | $																$ 23,613,000	$ 21,467,000
Series B Convertible Preferred Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)	18,000,000
Common stock issued (in shares)	30,000,000
Common stock issued, value | $																$ 8,767,000
Nasdaq Stock Market LLC [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of consecutive business days no longer able to meet the required closing bid price of common stock		30 days
Minimum bid price of common stock required for Nasdaq listing rule | $ / shares		$ 1
Grace period provided with minimum bid price for Nasdaq listing rule		180 days
Grace date for minimum bid price requirement for Nasdaq listing		Mar. 5, 2018
Common stock minimum bid price required to regain compliance | $ / shares		$ 1
Number of consecutive business days required to regain compliance		10 days
Additional grace period provided with minimum bid price to regain compliance		180 days
Date to regain compliance after meeting continued listing requirement		Sep. 4, 2018
Common Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock, shares outstanding (in shares)								57,825,729				21,707,890				57,825,729	21,707,890			13,003,893
Number of shares callable by warrants (in shares)								1								1
Common stock issued (in shares)	10,000					6,704,852										12,237,079	8,673,253
Each unit consist of number of warrant																0.5
Warrant exercise price (in dollars per share) | $ / shares	$ 0.3333							$ 3.06								$ 3.06
Common stock issued, value | $																$ 12,000	$ 9,000
Period exercisable from the date of issuance																30 months
Share issued, price per share | $ / shares				$ 1.10
Common Stock [Member] | Maxim Group LLC [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock issued (in shares)			849,000	8,600,000
Common stock, par value (in dollars per share) | $ / shares				$ 0.001
Share issued, price per share | $ / shares			$ 1.10	$ 1.0395
Proceeds from sale of common stock, net | $			$ 800,000	$ 8,700,000
Closing of offering date				Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter				45 days
Additional shares of common stock				944,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock issued, value | $					$ 20,000,000
Period exercisable from the date of issuance					30 months
Minimum [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Unrestricted cash and cash equivalents | $								$ 1,500,000								$ 1,500,000
2014 Equity Incentive Plan [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)							6,500,000												400,000

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Additional Information (Details) shares in Millions	1 Months Ended	12 Months Ended
	May 31, 2013	Dec. 31, 2017USD ($)CustomerSegmentshares	Dec. 31, 2016USD ($)CustomerDistributorSegmentshares
Summary Of Significant Accounting Policies [Line Items]
Cash equivalents investments with original maturities		$ 0	$ 0
Letters of credit issued in favour of landlord		500,000
Impairment loss		0	0
Impairment of goodwill		0	0
Acquired technology intangible assets		9,400,000
Useful life (in years)	11 years
Amortization expense		1,240,000	584,000
2,018		1,200,000
2,019		1,200,000
2,020		1,200,000
2,021		1,200,000
2,022		1,200,000
Thereafter		900,000
Accumulated amortization on intangible assets		$ 4,700,000	$ 3,400,000
Concentration risk percentage		100.00%	100.00%
Revenue recognized		$ 3,722,000	$ 6,724,000
Qualifying expenditures related to research		3,500,000	6,300,000
Interest or penalties related to income tax matters		$ 0	$ 0
Number of operating segment | Segment		1	1
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		20.5	4.2
Outstanding Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		19.5
Options and Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		1
BARDA Contract [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized		$ 3,700,000	$ 6,700,000
Customer Concentration Risk | Revenue Recognized [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer		5	3
Concentration risk percentage		68.00%	65.00%
Number of distributor | Distributor			2
Customer Concentration Risk | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer		1	2
Concentration risk percentage		77.00%	57.00%
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		5 years
Letter of Credit [Member]
Summary Of Significant Accounting Policies [Line Items]
Letters of credit amount pursuant to lease agreement		$ 200,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Intangibles, net:
Intangibles, net, Beginning balance	$ 8,447	$ 9,031
Intangibles, net, Amortization	(1,240)	(584)
Intangibles, net, Ending balance	7,207	8,447
Goodwill, net, Beginning balance	3,922	3,922
Goodwill, net Ending balance	3,922	3,922
Total goodwill and other intangibles, net	$ 11,129	$ 12,369

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Revenues	$ 662	$ 467	$ 969	$ 591	$ 1,466	$ 731	$ 1,126	$ 1,333	$ 2,689	$ 4,656
Concentration risk percentage									100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues									$ 345	$ 936
Concentration risk percentage									13.00%	20.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues									$ 1,924	$ 3,279
Concentration risk percentage									71.00%	71.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues									$ 344	$ 379
Concentration risk percentage									13.00%	8.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues									$ 76	$ 62
Concentration risk percentage									3.00%	1.00%

Transactions with Olympus Cor35

Transactions with Olympus Corporation (Details) - USD ($)	Apr. 30, 2015	Dec. 31, 2017
Termination of Olympus' Interest in the Joint Venture [Abstract]
Total purchase price	$ 6,000,000
Purchase price payment agreement term		2 years
Amendment One to Joint Venture Termination Agreement [Member]
Termination of Olympus' Interest in the Joint Venture [Abstract]
Purchase price payment termination agreement total	4,200,000
Purchase price principal amount payable on January 31, 2016	500,000
Purchase price principal amount payable on April 30, 2016	500,000
Purchase price principal amount and accrued interest payable on May 8, 2016	$ 800,000
Purchase price payable obligations outstanding balance.		$ 0

Fair Value - Fair Value and Car

Fair Value - Fair Value and Carrying Value of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 13,427	$ 17,611
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 13,624	$ 17,637

Disclosure - Fair Value - Addit

Disclosure - Fair Value - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt discount	$ 0.4	$ 1.2

Asset Purchase Agreement with38

Asset Purchase Agreement with Azaya Therapeutics - Additional Information (Details) - Azaya Therapeutics, Inc. [Member]	Feb. 15, 2017USD ($)CandidateEmployeeshares	Dec. 31, 2017USD ($)
Business Acquisition [Line Items]
Obligation to pay on existing payables assumed	$ 1,796,000
Total consideration	4,272,000
Fair value of the common stock issued	2,311,000
Assumed liabilities	1,800,000
Acquisition costs	200,000
Asset Purchase Agreement
Business Acquisition [Line Items]
Book value of tangible assets acquired	$ 3,000,000
Common stock, shares issued | shares	1,173,241
Common stock, shares issued after closing date | shares	879,931
Common stock deposited in escrow | shares	293,310
Obligation to pay on existing payables assumed	$ 1,800,000
Existing payables, paid during the period		$ 1,800,000
Number of employees | Employee	0
Maximum earn-out payment obligations	$ 100,000,000
Aggregate payment obligation threshold limit	$ 50,000,000
Percentage of net sales deemed for purposes of calculating payments	50.00%
Asset Purchase Agreement | IPR&D [Member]
Business Acquisition [Line Items]
Number of drug candidates acquired | Candidate	2

Asset Purchase Agreement with39

Asset Purchase Agreement with Azaya Therapeutics - Summery of Purchase Price Allocation on Fair Value Basis to Identifiable Net Assets (Details) - Azaya Therapeutics, Inc. [Member] $ in Thousands	Feb. 15, 2017USD ($)
Business Acquisition [Line Items]
Tangible assets	$ 2,586
Intangible assets	1,686
Total assets	4,272
Accounts payable	1,796
Fair value of the common stock issued	2,311
Transaction costs	165
Total consideration	$ 4,272

Composition of Certain Financ40

Composition of Certain Financial Statement Captions - Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventories, net [Abstract]
Raw materials	$ 681	$ 885
Work in process	722	1,021
Finished goods	1,780	1,819
Inventories, net	$ 3,183	$ 3,725

Composition of Certain Financ41

Composition of Certain Financial Statement Captions - Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Current Assets [Abstract]
Prepaid supplies or services, current	$ 544	$ 734
Prepaid insurance	556	83
Prepaid consumption tax in Japan	99	2
Other receivables	112	51
Total other current assets	$ 1,311	$ 870

Composition of Certain Financ42

Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property and Equipment, net [Abstract]
Manufacturing and development equipment	$ 4,507	$ 4,256
Office and computer equipment	1,805	1,953
Leasehold improvements	5,087	3,399
Property and equipment, gross	11,399	9,608
Less accumulated depreciation	(8,347)	(8,451)
Property and equipment, net	$ 3,052	$ 1,157

Composition of Certain Financ43

Composition of Certain Financial Statement Captions - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Composition Of Certain Financial Statement Captions [Abstract]
Depreciation expense	$ 0.9	$ 0.7

Composition of Certain Financ44

Composition of Certain Financial Statement Captions - Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Assets [Abstract]
Prepaid supplies, long-term	$ 2,181	$ 1,838
Deposits	389	498
Total other assets	$ 2,570	$ 2,336

Composition of Certain Financ45

Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable and Accrued Expenses [Abstract]
Accrued expenses	$ 1,599	$ 1,752
Accounts payable	1,297	1,332
Accrued payroll and bonus	810	989
Accrued legal fees	509	614
Accrued vacation	64	502
Accrued R&D studies	286	347
Other current liabilities	225	336
Accounts payable and accrued expenses, Total	$ 4,790	$ 5,872

Commitments and Contingencies46

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Feb. 27, 2017	Jan. 27, 2017	Dec. 31, 2017	Dec. 31, 2016
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months			$ 5,192
Initial term of lease	63 months
Lease commencement date	Jan. 1, 2018
Buy-out of obligations lease	$ 600
Japan Lease [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease		61 months
Lease commencement date			Apr. 15, 2017
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months			$ 600
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Rent expense			$ 2,200	$ 2,500

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Debt and Lease Payments (Details) $ in Thousands	Dec. 31, 2017USD ($)
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2,018	$ 5,192
2,019	8,877
Total	14,069
Payment on Lease Office and Manufacturing Space [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2,018	589
2,019	565
2,020	541
2,021	541
2,022	138
Total	$ 2,374

Commitments and Contingencies48

Commitments and Contingencies - Minimum Purchase Obligation (Details) $ in Thousands	Dec. 31, 2017USD ($)
Purchase Obligation Fiscal Year Maturity [Abstract]
2,018	$ 1,074
2,019	1,473
2,020	1,473
Total	$ 4,020

Long-term Obligations (Details)

Long-term Obligations (Details) - USD ($)		Dec. 29, 2017	May 29, 2015	Dec. 31, 2017	Dec. 31, 2016		Sep. 20, 2017	Jun. 15, 2016	May 11, 2016	May 10, 2016
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)								1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)								$ 3.06
Minimum liquidity covenant				$ 1,500,000
Future contractual principal and final fee payments on all debt and capital lease obligations [Abstract]
2,018				5,192,000
2,019				8,877,000
Total				14,069,000
Reconciliation of Face Value to Book Value [Abstract]
Total debt and lease obligations, including final payment fee (Face Value)				14,069,000
Less: Debt discount				(445,000)
Total obligation				13,624,000
Interest expense				2,049,000	$ 2,592,000
Non-cash amortization				$ 700,000	$ 1,000,000
LIBOR [Member] | Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate			1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date				May 29, 2015	May 29, 2015
Original Loan Amount			$ 17,700,000	$ 17,700,000	$ 17,700,000
Basis variable rate			7.95%
Maturity date				Jun. 1, 2019
Fees amount associated with loan			$ 1,100,000
Number of shares callable by warrants (in shares)			94,441
Warrant exercise price (in dollars per share)			$ 10.35
Date from which warrants are exercisable				Nov. 30, 2015
Warrant expiration date				May 29, 2025
Minimum liquidity covenant			$ 5,000,000				$ 1,500,000
Extended interest-only period				Aug. 1, 2018
Debt instrument, interest-only period				The amendment also extended the interest-only period under the Loan Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million before December 29, 2017.
Net proceeds excess receives from unrestricted cash		$ 5,000,000
Debt instrument, covenant compliance				we were in compliance with all of the debt covenants under the Loan and Security Agreement.
Additional details relating term loan that is outstanding [Abstract]
Origination Date				May 29, 2015	May 29, 2015
Original Loan Amount			$ 17,700,000	$ 17,700,000	$ 17,700,000
Interest Rate	[1]			8.95%	8.95%
Current Monthly Payment				$ 100,000	$ 136,000	[2],[3]
Original Term				48 months	48 months
Remaining Principal (Face Value)				$ 12,980,000	$ 17,700,000
Minimum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Interest rate			8.95%
Maximum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Original Loan Amount							3,000,000
Additional details relating term loan that is outstanding [Abstract]
Original Loan Amount							$ 3,000,000
[1]	3 month LIBOR rate with a floor of 1% plus 7.95%
[2]	Monthly payment as of December 2016, which reflects interest only
[3]	Monthly payment as of December 2017, which reflects interest only

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Provision or benefit for income taxes		$ 0	$ 0
Income Tax Contingency [Abstract]
Valuation allowance		97,089,000	$ 134,873,000
Increase (decrease) in valuation allowance		$ (37,800,000)
Corporate income tax rate		34.00%	34.00%
Net operating loss carryforwards, Expire date		Begin to expire in 2019 and 2017
State tax credit carryforwards		$ 4,500,000
Cumulative change in ownership		50.00%
Period of net operating loss and R&D tax credit carry forwards to offset future taxable income		3 years
Increase in income tax rate		$ 45,800,000
Decrease in net deferred tax assets		(45,800,000)
Liability for uncertain tax positions		$ 0	$ 0
Period for material changes of liability for uncertain tax benefits		12 months
Maximum [Member]
Income Tax Contingency [Abstract]
Corporate income tax rate		35.00%
Scenario Plan [Member]
Income Tax Contingency [Abstract]
Corporate income tax rate	21.00%
Federal [Member]
Income Tax Contingency [Abstract]
Tax loss carryforwards		$ 365,900,000
Federal tax carry forward		$ 5,100,000
Federal tax credit carryforward, Expiration date		Begin to expire in 2018
State [Member]
Income Tax Contingency [Abstract]
Tax loss carryforwards		$ 147,400,000

Income Taxes - Components of In

Income Taxes - Components of Income/(Loss) Before Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S.	$ (21,915)	$ (20,387)
Foreign	(771)	(1,659)
Income/(loss) before income tax provision (benefit)	$ (22,686)	$ (22,046)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Total Income Tax Provision (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of the total income tax provision tax rate [Abstract]
Income tax expense (benefit) at federal statutory rate	(34.00%)	(34.00%)
Income tax expense (benefit) at state statutory rate	(3.90%)	(3.40%)
Change in valuation allowance	(172.40%)	16.80%
Change in state rate	(0.80%)	(0.10%)
Permanent interest adjustments	0.20%	0.20%
Stock compensation	3.00%	12.70%
Research credit	(1.10%)	(1.40%)
Foreign rate differential	202.10%	0.80%
NOLs expiring and adjustments to NOL	7.00%	6.00%
Other, net	(0.20%)	2.50%
Total income tax provision	0.00%	0.00%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets [Abstract]
Allowances and reserves	$ 140	$ 573
Accrued expenses	154	701
Stock based compensation	1,065	1,947
Net operating loss carryforwards	87,426	125,182
Income tax credit carryforwards	8,587	7,764
Property and equipment, principally due to differences in depreciation	514	675
Other, net	45	48
Deferred tax assets (Total)	97,931	136,890
Valuation allowance	(97,089)	(134,873)
Total deferred tax assets, net of allowance	842	2,017
Deferred tax liabilities [Abstract]
Intangibles assets	(842)	(2,017)
Total deferred tax liability	(842)	(2,017)
Net deferred tax assets (liability)	$ 0	$ 0

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of reconciliation of unrecognized tax benefits activity [Roll Forward]
Unrecognized Tax Benefits – Beginning	$ 2,062	$ 1,987
Gross increases – tax positions in prior period	0	1
Gross decreases – tax positions in prior period	0	(13)
Gross increase – current-period tax positions	95	87
Unrecognized Tax Benefits – Ending	$ 2,157	$ 2,062

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Discretionary or matching contributions	$ 0	$ 0

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock (Details) - USD ($)	Nov. 28, 2017	Nov. 02, 2017	Jun. 16, 2016	Dec. 31, 2017	Dec. 31, 2016	Nov. 27, 2017	Jun. 15, 2016	May 11, 2016	May 10, 2016
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)				5,000,000	5,000,000
Preferred stock, par value (in dollars per share)				$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)				23,500	23,500
Series A convertible preferred stock, shares outstanding				2,431	0
Number of shares callable by warrants (in shares)							1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)							$ 3.06
Common stock issued (in shares)	10,000		6,704,852
Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)				1
Warrant exercise price (in dollars per share)	$ 0.3333			$ 3.06
Period exercisable from the date of issuance				30 months
Common stock issued (in shares)	10,000		6,704,852	12,237,079	8,673,253
Gross proceeds from private placement of stock			$ 15,300,000
Redemption price of warrant prior to expiration				$ 0.01
Common stock price per share for warrant redemption				$ 7.65
Number of consecutive trading days for warrant redemption				10 days
2017 Rights Offering [Member]
Preferred Stock [Abstract]
Charge on Non Transferable Subscription Rights		$ 0
Number of shares callable by warrants (in shares)		10,000
Warrant exercise price (in dollars per share)		$ 0.3333
Period exercisable from the date of issuance				30 months
Common stock issued (in shares)	10,000
Gross proceeds from private placement of stock	$ 8,800,000
Redemption price of warrant prior to expiration				$ 0.01
Common stock price per share for warrant redemption				$ 0.833
Number of consecutive trading days for warrant redemption				10 days
2017 Rights Offering [Member] | Warrant [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		18
2017 Rights Offering [Member] | Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Series A Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)				13,500	13,500
Convertible preferred stock				3.60%	3.60%
Series A convertible preferred stock, shares outstanding				0	0
Series B Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)						10,000
Preferred stock, par value (in dollars per share)						$ 0.001
Number of shares callable by warrants (in shares)	18,000,000
Common stock issued (in shares)	30,000,000
Percentage of preferred stock converted to common stock				75.00%
Series B Convertible Preferred Stock [Member] | Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable				$ 4,000,000
Series B Convertible Preferred Stock [Member] | 2017 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		10,000

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	Nov. 28, 2017	Dec. 22, 2016	Jun. 16, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 15, 2016	May 11, 2016	May 10, 2016
Common Stock [Abstract]
Each unit consist of number of warrant			3,352,306
Number of shares callable by warrants (in shares)						1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)						$ 3.06
Common stock issued (in shares)	10,000		6,704,852
Common stock issued, value				$ 12,716,000	$ 19,478,000
Proceeds from sale of common stock, net				$ 23,613,000	$ 21,467,000
Common Stock [Member]
Common Stock [Abstract]
Common Stock Subscription Price				$ 2.55
Each unit consist of number of common stock				1
Each unit consist of number of warrant				0.5
Number of shares callable by warrants (in shares)				1
Warrant exercise price (in dollars per share)	$ 0.3333			$ 3.06
Period exercisable from the date of issuance				30 months
Common stock issued (in shares)	10,000		6,704,852	12,237,079	8,673,253
Gross proceeds from private placement of stock			$ 15,300,000
Redemption price of warrant prior to expiration				$ 0.01
Common stock price per share for warrant redemption				$ 7.65
Number of consecutive trading days for warrant redemption				10 days
Common stock issued, value				$ 12,000	$ 9,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Period exercisable from the date of issuance		30 months
Common stock issued, value		$ 20,000,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member]
Common Stock [Abstract]
Common stock issued (in shares)		1,900,000
Common stock issued, value		$ 200,000
Proceeds from sale of common stock, net		$ 1,700,000
Common Stock [Member] | Securities Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		127,419
Trading Volume of Common Shares		0
Common stock issued (in shares)		382,258
Common Stock [Member] | Maximum [Member] | Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member]
Common Stock [Abstract]
Floor price of per share		$ 0.50
Common Stock [Member] | Maximum [Member] | Single Regular Purchase [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		100,000
Common Stock [Member] | Minimum [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding		9.99%
Common Stock [Member] | Minimum [Member] | Single Regular Purchase [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value		$ 1,000,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	May 31, 2017	Jan. 31, 2017	May 31, 2016	Dec. 29, 2015	Aug. 31, 2015	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Securities remaining and available for future issuances (in shares)						6,208,390
Stock Option Activity [Abstract]
Stock option vesting period						4 years
Stock option contractual term						10 years
Stock option vesting provisions						12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or 1/48 of the award will vest at the end of each month over a four-year period.
Weighted Average Remaining Contractual Terms [Abstract]
Stock options exercised						$ 0	$ 0
Dividend yield assumed						0
Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards						$ 600,000
Weighted average period for recognition of cost						1 year 6 months
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares to be issued (in shares)	2,000,000		333,333		301,800	265,000
Securities remaining and available for future issuances (in shares)						2,060,504
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares to be issued (in shares)		250,000		66,666
Securities remaining and available for future issuances (in shares)						304,166

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Options [Roll Forward]
Balance as of January 1, 2017 (in shares) | shares	636,112
Granted (in shares) | shares	710,600
Expired (in shares) | shares	(19,450)
Cancelled/forfeited (in shares) | shares	(316,944)
Balance as of December 31, 2017 (in shares) | shares	1,010,318
Weighted Average Exercise Price [Roll Forward]
Balance as of January 1, 2017 (in dollars per share) | $ / shares	$ 24.39
Granted (in dollars per share) | $ / shares	1.47
Expired (in dollars per share) | $ / shares	82.46
Cancelled/forfeited (in dollars per share) | $ / shares	9.06
Balance as of December 31, 2017 (in dollars per share) | $ / shares	$ 11.96

Stock-based Compensation - St60

Stock-based Compensation - Stock Options Vested and Expected to Vest (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Options [Roll Forward]
Balance as of December 31, 2017 (in shares)	1,010,318	636,112
Vested and expected to vest at December 31, 2017(in shares)	893,185
Exercisable at December 31, 2017 (in shares)	401,599
Weighted Average Exercise Price [Roll Forward]
Balance as of December 31, 2017 (in dollars per share)	$ 11.96
Vested and expected to vest at December 31, 2017 (in dollars per share)	13.35
Exercisable at December 31, 2017 (in dollars per share)	$ 26.89
Weighted Average Remaining Contractual Term [Roll Forward]
Balance as of December 31, 2017	7 years 11 months 12 days
Vested and expected to vest at December 31, 2017	7 years 9 months 18 days
Exercisable at December 31, 2017	6 years 5 months 12 days

Stock-based Compensation - Weig

Stock-based Compensation - Weighted-average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]
Expected term	6 years 7 months 6 days	6 years
Risk-free interest rate	2.20%	1.75%
Volatility	78.84%	77.56%
Resulting weighted average grant date fair value (in dollars per share)	$ 1.05	$ 1.84

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost Recognized for Stock Options and Restricted Stock Awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Compensation cost recognized for the stock options and restricted stock awards [Abstract]
Total compensation cost for share-based payment arrangements recognized in the statement of operations	$ 753	$ 1,080

Quarterly Information (unaudi63

Quarterly Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Line Items]
Product revenues	$ 662	$ 467	$ 969	$ 591	$ 1,466	$ 731	$ 1,126	$ 1,333	$ 2,689	$ 4,656
Gross profit	29	(20)	262	(125)	521	113	541	766	146	1,941
Development revenues	867	1,306	531	1,018	1,561	1,879	1,699	1,585
Operating expenses	(4,526)	(5,629)	(6,374)	(6,336)	(5,670)	(6,789)	(8,464)	(7,448)
Other expense, net	(656)	(464)	(468)	(415)	(1,330)	(587)	(181)	(242)	(2,003)	(2,340)
Net loss	(4,286)	(4,807)	(6,049)	(7,544)	(4,918)	(5,384)	(6,405)	(5,339)	(22,686)	(22,046)
Beneficial conversion feature for convertible preferred stock	(3,977)	0	0	0	0	0	0	0	(3,977)	0
Net loss allocable to common stockholders	$ (8,263)	$ (4,807)	$ (6,049)	$ (7,544)	$ (4,918)	$ (5,384)	$ (6,405)	$ (5,339)	$ (26,663)	$ (22,046)
Basic and diluted net loss per share	$ (0.20)	$ (0.14)	$ (0.19)	$ (0.33)	$ (0.24)	$ (0.26)	$ (0.43)	$ (0.41)	$ (0.82)	$ (1.28)
Azaya Therapeutics, Inc. [Member]
Quarterly Financial Information Disclosure [Line Items]
In process research and development acquired from Azaya				$ (1,686)					$ (1,686)	$ 0

SCHEDULE II - VALUATION AND Q64

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of year		$ 167	$ 797
Additions	[1]	0	0
Deductions	[2]		(630)
Balance at end of year		$ 167	$ 167
[1]	Includes charges to costs and expenses
[2]	Deductions for uncollectible accounts receivable includes payments collected and devices recovered from customers